机构:[1]Univ Sydney, George Inst Global Hlth, Div Cardiovasc, Sydney, NSW 2006, Australia;[2]Peking Univ, Hlth Sci Ctr, George Inst Global Hlth, Beijing 100871, Peoples R China;[3]Capital Med Univ, Beijing Anzhen Hosp, Beijing, Peoples R China;首都医科大学附属安贞医院[4]Peking Univ, Hlth Sci Ctr, Clin Res Inst, Beijing 100871, Peoples R China;[5]Chinese Acad Med Sci, Cardiovasc Inst, Dept Cardiol, Peking Union Med Coll, Beijing 100730, Peoples R China;[6]Chinese Acad Med Sci, Fuwai Hosp, Peking Union Med Coll, Beijing 100730, Peoples R China;[7]NSW Minist Hlth, Agcy Clin Innovat, Sydney, NSW, Australia;[8]Peking Univ, Peoples Hosp, Dept Cardiol, Beijing 100871, Peoples R China;[9]George Inst Global Hlth, Div Cardiovasc, Level 10,King George V Bldg,83-117 Missenden Rd, Camperdown, NSW 2050, Australia
Background- Organizational and wider health system factors influence the implementation and success of interventions. Clinical Pathways in Acute Coronary Syndromes 2 is a cluster randomized trial of a clinical pathway-based intervention to improve acute coronary syndrome care in hospitals in China. We performed a qualitative evaluation to examine the system-level barriers to implementing clinical pathways in the dynamic healthcare environment of China. Methods and Results- A qualitative descriptive analysis of 40 in-depth interviews with health professionals conducted in a sample of 10 hospitals purposively selected to explore barriers to implementation of the intervention. Qualitative data were analyzed using the Framework method. In-depth interviews identified 5 key system-level barriers to effective implementation: (1) leadership support for implementing quality improvement, (2) variation in the capacity of clinical services and quality improvement resources, (3) fears of patient disputes and litigation, (4) healthcare funding constraints and high out-of-pocket expenses, and (5) patient-related factors. Conclusions- System-level barriers affect the ability of acute coronary syndrome clinical pathways to change practice. Addressing these barriers in the context of current and planned national health system reform will be critical for future improvements in the management of acute coronary syndromes, and potentially other hospitalized conditions, in China. Clinical Trial Registration- URL: http://www.anzctr.org.au/default.aspx. Register. Unique identifier: ACTRN12609000491268.
第一作者机构:[1]Univ Sydney, George Inst Global Hlth, Div Cardiovasc, Sydney, NSW 2006, Australia;
通讯作者:
通讯机构:[1]Univ Sydney, George Inst Global Hlth, Div Cardiovasc, Sydney, NSW 2006, Australia;[9]George Inst Global Hlth, Div Cardiovasc, Level 10,King George V Bldg,83-117 Missenden Rd, Camperdown, NSW 2050, Australia
推荐引用方式(GB/T 7714):
Ranasinghe Isuru,Rong Ye,Du Xin,et al.System Barriers to the Evidence-Based Care of Acute Coronary Syndrome Patients in China Qualitative Analysis[J].CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES.2014,7(2):209-216.doi:10.1161/CIRCOUTCOMES.113.000527.
APA:
Ranasinghe, Isuru,Rong, Ye,Du, Xin,Wang, Yangfang,Gao, Runlin...&Turnbull, Fiona.(2014).System Barriers to the Evidence-Based Care of Acute Coronary Syndrome Patients in China Qualitative Analysis.CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES,7,(2)
MLA:
Ranasinghe, Isuru,et al."System Barriers to the Evidence-Based Care of Acute Coronary Syndrome Patients in China Qualitative Analysis".CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES 7..2(2014):209-216